Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak

S. H. Lee, J. J. Yim, H. J. Kim, T. S. Shim, H. S. Seo, Y. S. Cho, H. K. Lee, Y. M. Lee, E. J. Lee, W. J. Lew

    Research output: Contribution to journalArticlepeer-review

    9 Citations (Scopus)

    Abstract

    We screened tuberculosis (TB) contacts as an outbreak investigation with tuberculin skin test (TST) and interferon-gamma release assay (IGRA). We evaluated adverse events and TB incidence in all persons screened after rifampicin (RFP) prophylaxis, and specifically assessed the new TB cases in relation to initial TST and IGRA results. The 180 contacts were divided into four groups: TST+/IGRA+ (n=101), TST+/IGRA- (n=22), TST-/IGRA+ (n=16), and TST-/IGRA- (n=41). RFP treatment (4 months) was prescribed only to the TST+/IGRA+ group. Of 87 contacts who initiated prophylaxis, adverse events occurred in 21 contacts (24·1%) including hepatotoxicity (11·5%), flu-like syndrome (5·7%), and thrombocytopenia (3·4%). TB developed in two TST+/IGRA+ subjects after completion of prophylaxis, including one multidrug-resistant (MDR)-TB case during 21·8 months of follow-up. Adverse events were frequent, and development of TB including MDR-TB occurred after RFP prophylaxis.

    Original languageEnglish
    Pages (from-to)1028-1035
    Number of pages8
    JournalEpidemiology and Infection
    Volume140
    Issue number6
    DOIs
    Publication statusPublished - 2012 Jun

    Keywords

    • Antibiotic prophylaxis
    • drug toxicity
    • multidrug-resistant tuberculosis
    • rifampicin
    • tuberculosis

    ASJC Scopus subject areas

    • Epidemiology
    • Infectious Diseases

    Fingerprint

    Dive into the research topics of 'Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak'. Together they form a unique fingerprint.

    Cite this